secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001104659-25-018635
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia loses court challenge to FDA's Tyvaso DPI exclusivity; cross claim still pending
--------------------------------------------------------------------------------

- On Feb 27, 2025, District Court denied Liquidia's summary judgment motion, affirming FDA's 3-year exclusivity for Tyvaso DPI.
- Exclusivity expiration remains May 23, 2025; decision does not change that date.
- United Therapeutics' cross claim challenging FDA's acceptance of Liquidia's amended NDA remains pending; dismissal motions not yet ruled on.
- Liquidia filed lawsuit in August 2024; this ruling is a legal setback for their NDA approval timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925018635/0001104659-25-018635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925018635/tm257909d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer